AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33323767 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study 33323786 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection Pressure (IP) and Minimum Intensity of Stimulation (MIS) during PNB
Number of subjects: 28
Study 33323786 — intervention group
Group type: EXPERIMENTAL
Intervention: CART algorithm for needle tip position
Number of subjects: 28
Study 33323870 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk subjects (CVD risk factors)
Number of subjects: 49
Study 33323870 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 49
Study 33324041 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (563.3±1.3 μg/d, n=551)
Number of subjects: 723
Study 33324041 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone/salmeterol (1013.8±1.4 μg/d, n=172)
Number of subjects: 723
Study 33324041 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 723
Study 33324041 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone/salmeterol
Number of subjects: 723
Study 33324255 — intervention group
Group type: COMPARATOR
Intervention: Nabiximols, dosage and duration not specified
Number of subjects: 0
Study 33324299 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-AFTERc intervention
Number of subjects: 0
Study 33324323 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Virtual Environments for hand-focused rehabilitation
Number of subjects: 0
Study 33324323 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33324397 — intervention group
Group type: EXPERIMENTAL
Intervention: UV1 vaccination with GM-CSF as adjuvant
Number of subjects: 18
Study 33324882 — intervention group
Group type: EXPERIMENTAL
Intervention: FEES (Flexible Endoscopic Evaluation of Swallowing)
Number of subjects: 2401
Study 33324884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Stroke Unit (MSU) care
Number of subjects: 0
Study 33324884 — intervention group
Group type: COMPARATOR
Intervention: Regular ambulances (Control group)
Number of subjects: 0
Study 33324884 — intervention group
Group type: EXPERIMENTAL
Intervention: MSU care with additional use of information from registration offices
Number of subjects: 0
Study 33324891 — intervention group
Group type: COMPARATOR
Intervention: Programming algorithm for deep brain stimulation
Number of subjects: 40
Study 33324891 — intervention group
Group type: COMPARATOR
Intervention: Monopolar review to identify the best therapeutic contact
Number of subjects: 40
Study 33324891 — intervention group
Group type: COMPARATOR
Intervention: Acute improvement of dystonia
Number of subjects: 40
Study 33324891 — intervention group
Group type: COMPARATOR
Intervention: Induction of phosphenes
Number of subjects: 40
Study 33324894 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported Outcomes Measurement Information System 10-Question Short Form (PROMIS-10)
Number of subjects: 1040
Study 33324894 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Health Questionnaire-4
Number of subjects: 1040
Study 33324894 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified modified Ranking Scale questionnaire
Number of subjects: 1040
Study 33324894 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative semi-structured interviews with clinical staff and patients
Number of subjects: 1040
Study 33324894 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analyses of data quality
Number of subjects: 1040
Study 33324899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (2-4 g/day)
Number of subjects: 0
Study 33324899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33324905 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 150
Study 33324905 — intervention group
Group type: COMPARATOR
Intervention: Interferon [IFN]-β1a (active comparator)
Number of subjects: 150
Study 33324913 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study 33324913 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 33324916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand motor score (Fugl-Meyer Assessment) at 12 months after enrollment
Number of subjects: 0
Study 33324916 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive clinical evaluations at baseline, 3, 6, and 12 months
Number of subjects: 0
Study 33324916 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of primary outcome analyzed using linear regression analysis
Number of subjects: 0
Study 33324926 — intervention group
Group type: EXPERIMENTAL
Intervention: Vojta therapy
Number of subjects: 40
Study 33324926 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 40
Study 33324925 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratentorial lacunar infarcts
Number of subjects: 224
Study 33324925 — intervention group
Group type: EXPERIMENTAL
Intervention: Infratentorial lacunar infarcts
Number of subjects: 224
Study 33324925 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS score on hospital arrival
Number of subjects: 224
Study 33324925 — intervention group
Group type: EXPERIMENTAL
Intervention: Median infarct volume
Number of subjects: 224
Study 33324931 — intervention group
Group type: EXPERIMENTAL
Intervention: EVT + IVT (Endovascular Therapy with Intravenous Thrombolysis)
Number of subjects: 166
Study 33324931 — intervention group
Group type: COMPARATOR
Intervention: EVT alone
Number of subjects: 166
Study 33324941 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective neurostimulation of the nucleus basalis of Meynert (NBM)
Number of subjects: 12
Study 33324941 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation of the nucleus basalis of Meynert (NBM)
Number of subjects: 12
Study 33324941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bilateral STN- and NBM-DBS
Number of subjects: 12
Study 33324993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1157
Study 33324993 — intervention group
Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 1157
Study 33325055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegzilarginase (AEB1102), administered intravenously once weekly at a mean dose of 0.10 mg/kg for 20 cumulative doses.
Number of subjects: 16
Study 33325055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegzilarginase (AEB1102)
Number of subjects: 16
Study 33325459 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening colonoscopies
Number of subjects: 6925
Study 33325459 — intervention group
Group type: COMPARATOR
Intervention: All colonoscopies
Number of subjects: 6925
Study 33325531 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA patients with obesity
Number of subjects: 100
Study 33325531 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA patients with hypertension
Number of subjects: 100
Study 33325531 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA patients with Charlson Comorbidity Index (CCI) ≥1
Number of subjects: 100
Study 33325531 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA patients with obesity, hypertension, widespread pain, and CCI ≥1
Number of subjects: 100
Study 33325531 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA patients
Number of subjects: 100
Study 33325570 — intervention group
Group type: COMPARATOR
Intervention: Simulation-based obstetric team training
Number of subjects: 1000
Study 33325614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF) estimated through a submaximal treadmill test
Number of subjects: 65
Study 33325614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic discrimination task performance
Number of subjects: 65
Study 33325614 — intervention group
Group type: EXPERIMENTAL
Intervention: Left anterior DG/CA3 volume
Number of subjects: 65
Study 33325614 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF
Number of subjects: 65
Study 33325833 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation Game (SG) Effic'Asthme
Number of subjects: 42
Study 33325833 — intervention group
Group type: COMPARATOR
Intervention: Multiple Choice Questionnaire (MCQ)
Number of subjects: 42
Study 33325838 — intervention group
Group type: EXPERIMENTAL
Intervention: HMP 2.0 app-based intervention
Number of subjects: 1050
Study 33325838 — intervention group
Group type: COMPARATOR
Intervention: Information-only app-based control arm
Number of subjects: 1050
Study 33325838 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher-created network arm of HMP 2.0
Number of subjects: 1050
Study 33325838 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-referred network arm of HMP 2.0
Number of subjects: 1050
Study 33325838 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected biomarkers (viral load) for participants living with HIV
Number of subjects: 1050
Study 33325838 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing kits for HIV-negative participants
Number of subjects: 1050
Study 33326342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-valent human papillomavirus (9vHPV) vaccine
Number of subjects: 2029
Study 33326662 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread myofascial dysfunction and sensitisation
Number of subjects: 30
Study 33326662 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread myofascial dysfunction
Number of subjects: 30
Study 33326662 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal segmental sensitisation
Number of subjects: 30
Study 33326662 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic sensitisation
Number of subjects: 30
Study 33326662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbosacral/pelvic sensitisation
Number of subjects: 30
Study 33326662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical sensitisation
Number of subjects: 30
Study 33326662 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial pain
Number of subjects: 30
Study 33326662 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread sensitisation
Number of subjects: 30
Study 33326662 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful body areas
Number of subjects: 30
Study 33326710 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 73
Study 33326935 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 (n = 292 person-days)
Number of subjects: 16
Study 33326935 — intervention group
Group type: COMPARATOR
Intervention: Method 2 (n = 282 person-days)
Number of subjects: 16
Study 33326935 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1
Number of subjects: 16
Study 33326935 — intervention group
Group type: COMPARATOR
Intervention: Method 2
Number of subjects: 16
Study 33327047 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg once daily in continuous 28-day cycles)
Number of subjects: 20
Study 33327268 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral neutrophil-to-lymphocyte ratio
Number of subjects: 0
Study 33327268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes
Number of subjects: 0
Study 33327953 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion at a hemoglobin concentration of 8 g/dl (lower-threshold)
Number of subjects: 192
Study 33327953 — intervention group
Group type: COMPARATOR
Intervention: Transfusion at a hemoglobin concentration of 10 g/dl (higher-threshold)
Number of subjects: 192
Study 33327960 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual interviews with older persons
Number of subjects: 36
Study 33328058 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep residual networks for automated detection of COPD
Number of subjects: 2153
Study 33328176 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33328257 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33328261 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted sedation after initiation of mechanical ventilation in the ED
Number of subjects: 344
Study 33328261 — intervention group
Group type: COMPARATOR
Intervention: Before intervention (baseline)
Number of subjects: 344
Study 33328261 — intervention group
Group type: EXPERIMENTAL
Intervention: After intervention
Number of subjects: 344
Study 33328761 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day of oral ASP0819
Number of subjects: 186
Study 33328761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 33329075 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-listening intervention, details on dosage and duration not available
Number of subjects: 0
Study 33329075 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 33329103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Crisis Intervention
Number of subjects: 0
Study 33329303 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study 33329303 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant immunosuppressive therapy
Number of subjects: 0
Study 33329303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33329326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Rehabilitation Program
Number of subjects: 0
Study 33329329 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive treatment for active MRI lesions in MS, specific intervention details not available.
Number of subjects: 0
Study 33329334 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation, details not available
Number of subjects: 0
Study 33329400 — intervention group
Group type: EXPERIMENTAL
Intervention: Admittance dysnatremia
Number of subjects: 0
Study 33329400 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33330029 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic Center (DC)
Number of subjects: 64
Study 33330029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 33330051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with anthracycline-containing neoadjuvant chemotherapy
Number of subjects: 0
Study 33330076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sector irradiation (SR)
Number of subjects: 40
Study 33330076 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain irradiation therapy (WBRT)
Number of subjects: 40
Study 33330535 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal Humidified Rapid Insufflation Ventilatory Exchange with Nasopharyngeal Airway
Number of subjects: 0
Study 33330535 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33330736 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic ACL tear classification system
Number of subjects: 75
Study 33330959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) 2 mg at baseline
Number of subjects: 16
Study 33331203 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic septum resection (HSR)
Number of subjects: 4
Study 33331207 — intervention group
Group type: EXPERIMENTAL
Intervention: BioMimics 3D Vascular Stent System
Number of subjects: 271
Study 33331663 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Number of subjects: 238
Study 33331662 — intervention group
Group type: COMPARATOR
Intervention: Lumacaftor-ivacaftor (600 mg or 400 mg once daily)
Number of subjects: 2959
Study 33331662 — intervention group
Group type: COMPARATOR
Intervention: Lumacaftor-ivacaftor (200 mg twice daily)
Number of subjects: 2959
Study 33331662 — intervention group
Group type: COMPARATOR
Intervention: Tezacaftor-ivacaftor (100 mg twice daily)
Number of subjects: 2959
Study 33331662 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor-tezacaftor-ivacaftor (triple therapy)
Number of subjects: 2959
Study 33331662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapies (lumacaftor-ivacaftor, tezacaftor-ivacaftor)
Number of subjects: 2959
Study 33331662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor
Number of subjects: 2959
Study 33331662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezacaftor-ivacaftor
Number of subjects: 2959
Study 33331662 — intervention group
Group type: COMPARATOR
Intervention: Corrector monotherapy
Number of subjects: 2959
Study 33331670 — intervention group
Group type: EXPERIMENTAL
Intervention: Emixustat
Number of subjects: 821
Study 33331670 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 821
Study 33331670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 33331692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 0
Study 33331830 — intervention group
Group type: EXPERIMENTAL
Intervention: SelFIT program plus care as usual (CAU)
Number of subjects: 240
Study 33331830 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 240
Study 33331996 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3026 (200 mg)
Number of subjects: 29
Study 33331996 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3026 (325 mg)
Number of subjects: 29
Study 33331996 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3026 (75 mg)
Number of subjects: 29
Study 33331996 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3026 (125 mg)
Number of subjects: 29
Study 33331996 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3026 (various doses)
Number of subjects: 29
Study 33332484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 0
Study 33332545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime/zidebactam
Number of subjects: 0
Study 33332545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime/taniborbactam
Number of subjects: 0
Study 33332545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime/enmetazobactam
Number of subjects: 0
Study 33332545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime/tazobactam
Number of subjects: 0
Study 33332545 — intervention group
Group type: COMPARATOR
Intervention: Cefepime/enmetazobactam and cefepime/taniborbactam
Number of subjects: 0
Study 33332761 — intervention group
Group type: EXPERIMENTAL
Intervention: IV recombinant human arylsulfatase A (rhASA) at 50, 100, or 200 U/kg body weight every 14 (± 4) days for 52 weeks
Number of subjects: 13
Study 33332761 — intervention group
Group type: EXPERIMENTAL
Intervention: IV recombinant human arylsulfatase A (rhASA) at 100 or 200 U/kg during a 24-month extension period
Number of subjects: 13
Study 33332922 — intervention group
Group type: EXPERIMENTAL
Intervention: LowTAC/EVR combination
Number of subjects: 0
Study 33332922 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscalimab monoclonal antibody
Number of subjects: 0
Study 33332922 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (anti-C5 monoclonal antibody)
Number of subjects: 0
Study 33332922 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal complement C1 inhibition
Number of subjects: 0
Study 33333899 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment
Number of subjects: 0
Study 33333899 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33334337 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional delivery
Number of subjects: 413377
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age > 35
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: No maternal education
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower education
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity > 2
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructed labor
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe antepartum hemorrhage
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive disorders
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician attendance at delivery
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery in hospital
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean delivery
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mortality ratio (MMR)
Number of subjects: 571321
Study 33334343 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR range
Number of subjects: 571321
Study 33334356 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth
Number of subjects: 272192
Study 33334356 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (LBW)
Number of subjects: 272192
Study 33334356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of preterm birth and LBW
Number of subjects: 272192
Study 33334356 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for preterm birth and LBW
Number of subjects: 272192
Study 33334359 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Network Socioeconomic Status Index (10-item index)
Number of subjects: 49536
Study 33334365 — intervention group
Group type: EXPERIMENTAL
Intervention: African sites (Zambia and Kenya)
Number of subjects: 0
Study 33334365 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian sites (Belagavi and Nagpur, India and Pakistan)
Number of subjects: 0
Study 33334365 — intervention group
Group type: EXPERIMENTAL
Intervention: Central American site (Guatemala)
Number of subjects: 0
Study 33334365 — intervention group
Group type: COMPARATOR
Intervention: South Asian sites (India and Pakistan)
Number of subjects: 0
Study 33334365 — intervention group
Group type: COMPARATOR
Intervention: African sites (Kenya and Zambia)
Number of subjects: 0
Study 33334365 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 0
Study 33334422 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in diastolic dysfunction grade/grade 1 DD at 30 days post-TAVR
Number of subjects: 1750